MAP2K7 and kidney cancer: Furthermore, the activation of the NFKB1‐MYC link in FBW7‐deficient cells seems to sensitize them to Sorafinib (a MEK‐Raf inhibitor), a drug used in treatment of primary kidney cancer (Huang et al, 2014).